Medical Oncologist
CION Cancer Clinics
CYP2D6 and tamoxifen: what the gene test can and cannot tell you | CION Cancer Clinics
Tamoxifen works best after the liver turns it into a stronger form, and an enzyme made by the CYP2D6 gene does most of that work. Some people inherit a slower version of the gene. Whether that makes tamoxifen less protective is still debated, so most guidelines do not test everyone. This page explains the result labels, the medicines that interfere, and what a result may change. At CION Cancer Clinics, our team helps carriers and their families plan checks, next steps and support after a genetic result.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does the CYP2D6 gene have to do with tamoxifen?
- Poor, intermediate, normal or ultrarapid: what does each label mean?
- What happens to a tamoxifen tablet after you swallow it?
- The words you will meet, in plain language
- What a low-activity result may change, and what it does not
- What this page cannot tell you
- Four things patients tell us, and what is actually true
- Common questions about CYP2D6 and tamoxifen
The short answer
What does the CYP2D6 gene have to do with tamoxifen?
Tamoxifen has to be changed by the liver into a stronger form before it works well. A liver enzyme made from the CYP2D6 gene does most of that work. People inherit different versions of this gene, so some make much less of the strong form than others.
Why this became a question at all
Tamoxifen is a hormone tablet for breast cancers that grow in response to oestrogen. It is taken daily for years after surgery, often by younger women who have not reached menopause. If a woman's body makes little of the working form, doctors reasonably asked whether the tablet protects her as well as it protects others.
What the evidence says so far
Studies have not agreed. Some found that women with low enzyme activity did worse, while several large trial analyses found no clear difference. Because of that, most cancer guidelines do not ask for this test before every tamoxifen prescription. It is an inherited result, so it describes your body, not your tumour.
This test does not decide whether hormone treatment is right for you. Your tumour's hormone receptor result does that.The four labels
Poor, intermediate, normal or ultrarapid: what does each label mean?
A CYP2D6 report usually sorts you into one of four groups, based on the two copies of the gene you inherited.
Poor metaboliser
Neither copy of the gene works, or both work very little. The body makes far less of tamoxifen's working form. This is the group where a doctor is most likely to discuss an alternative hormone medicine.
Intermediate metaboliser
One copy works less well than usual. Enzyme activity sits somewhere between poor and normal. What to do with this result is less clear, and advice varies between doctors.
Normal metaboliser
Both copies work as expected. Tamoxifen is converted in the usual way, and the result does not suggest any change to the plan.
Still worth knowing
- Some other medicines can lower the enzyme's activity
- A normal gene does not protect against those medicines
Ultrarapid metaboliser
Extra copies of the gene make the enzyme unusually active. For tamoxifen this is not thought to be harmful. It matters more for some pain medicines, such as codeine, which is worth telling any doctor.
Not sure whether this applies to you?
Ask an oncologistFrom tablet to working medicine
What happens to a tamoxifen tablet after you swallow it?
-
The tablet is absorbed from the gut
Tamoxifen passes into the blood and travels to the liver. In this first form it has only a weak effect on breast cancer cells.
-
Liver enzymes reshape it
Several enzymes work on tamoxifen in turn. Each step changes the molecule a little, producing a family of related substances.
-
CYP2D6 makes the strongest form
The most important product is called endoxifen. The CYP2D6 enzyme carries out the key step that produces it. Less enzyme activity means less endoxifen in the blood.
-
Endoxifen blocks oestrogen at the cancer cell
It sits on the oestrogen receptor and stops oestrogen switching the cell on. This is how tamoxifen lowers the chance of the cancer coming back.
-
Other things change the level too
The gene is only one part of the picture. Other medicines, how regularly the tablet is taken and differences between bodies all affect how much endoxifen is made.
On your report
The words you will meet, in plain language
- CYP2D6
- The name of the gene, and of the liver enzyme it makes. It handles many common medicines, not only tamoxifen.
- Genotype
- The exact versions of the gene you inherited, one from each parent. They are written as short codes with a star, such as a star-one.
- Phenotype
- What those versions mean in practice: poor, intermediate, normal or ultrarapid enzyme activity.
- Activity score
- A number some reports use to turn the genotype into a phenotype. It is a label for the enzyme, not a risk score for cancer.
- Endoxifen
- The strongest working form of tamoxifen, made mainly through CYP2D6.
- Inhibitor
- A medicine that slows the enzyme down. It can make a normal metaboliser behave like a poor one while it is being taken.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Side by side
What a low-activity result may change, and what it does not
What it may change
What it does not change
Your oncologist may discuss a different hormone tablet
Whether you need hormone treatment at all
Which antidepressant is chosen for hot flushes or mood
Your surgery, radiotherapy or chemotherapy plan
What you tell other doctors about pain medicines
Your inherited risk of cancer, or your family's
How closely side effects are reviewed
The need to keep taking your tablet every day
Being straight with you
What this page cannot tell you
It cannot tell you whether to stay on tamoxifen or switch. That depends on your age, whether you have reached menopause, your other health conditions and the details of your cancer. Only your oncologist has all of those in front of them.
It cannot read a report you are holding
Laboratories test different sets of gene versions, and the CYP2D6 gene is harder to read than most because a very similar gene sits beside it. Two labs can describe the same person slightly differently. What your specific result means is a question for the oncologist or counsellor who ordered the test.
Who this does not apply to
Most people reading this do not need the test. If you take letrozole, anastrozole or exemestane, CYP2D6 plays no part in how those tablets work. If your cancer is not hormone sensitive, tamoxifen is not part of your plan. And this is not the tumour test that guides targeted drugs, which looks at the cancer itself rather than at you.
Never stop or change tamoxifen on the strength of a gene result alone. Talk to your oncologist first.Commonly believed
Four things patients tell us, and what is actually true
"If I am a poor metaboliser, tamoxifen is useless for me."
Not proven. Poor metabolisers make less of the working form, but studies have not shown clearly that their cancer comes back more often. The tablet may still give real protection.
"Everyone on tamoxifen should have this test."
Most cancer guidelines do not recommend routine testing. Some doctors order it for particular situations, such as a younger woman who could reasonably take a different tablet.
"A normal result means no medicine can affect my tamoxifen."
Some antidepressants, including paroxetine and fluoxetine, block the enzyme strongly. They can lower endoxifen even in someone with normal genes, which is why your oncologist should see every medicine you take.
"My daughter should be tested because I was."
This result is about how you handle one medicine. It says nothing about cancer risk in the family. A relative would only need it if she were ever prescribed tamoxifen herself.
Questions we are asked
Common questions about CYP2D6 and tamoxifen
Should I be tested before starting tamoxifen?
Usually not. Most cancer guidelines do not ask for it, because the evidence on outcomes is mixed. It may be worth discussing if you are young, expect a long course of tamoxifen and could safely take a different hormone medicine. Your oncologist can tell you whether that describes you.
I am a poor metaboliser. Should I stop tamoxifen?
Do not stop on your own. Stopping hormone treatment early is a known reason for cancer returning. If you are a poor metaboliser, your oncologist may consider an alternative, such as an aromatase inhibitor, sometimes with medicine to rest the ovaries if you have not reached menopause.
Which medicines interfere with tamoxifen through CYP2D6?
The best-known are the antidepressants paroxetine and fluoxetine, and bupropion, which is also used to stop smoking. They are sometimes prescribed for hot flushes or low mood. If you need one, your doctor can usually choose an option such as venlafaxine that interferes far less.
Is this a blood test or a tissue test?
A blood test or a cheek swab. It reads the genes you were born with, so it does not need any tumour tissue. The result does not change over your lifetime, which means it only ever needs to be done once.
Does CYP2D6 affect letrozole or anastrozole?
No. These aromatase inhibitors work in a different way and do not rely on CYP2D6 to become active. That is one reason they are the usual alternative when a doctor has doubts about tamoxifen for a woman who has reached menopause.
Can a blood level of endoxifen be measured instead?
It can be measured in some research and specialist settings, but it is not a routine test in India. Doctors have not agreed on a level that should trigger a change in treatment, so it is rarely used to make decisions today.
Does this result matter for any other medicines?
Yes. CYP2D6 handles many common medicines, including codeine, tramadol, some antidepressants and some anti-sickness tablets. Keep a copy of the report and show it to any doctor who prescribes for you, not only your oncologist.
Is CYP2D6 testing covered by insurance or Aarogyasri?
Usually not, because it is not part of routine tamoxifen treatment. It is normally paid for directly to the laboratory. Ask the lab for the full price, including sample collection, before the sample is taken.
Your Specialists
Meet CION's oncologists. Bring your family history or genetic report to them.
Our medical oncologists see people with a strong family history of cancer, arrange genetic counselling and testing where it fits, and plan the checks that follow.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- Clinical Pharmacogenetics Implementation Consortium (CPIC) — CPIC Guideline for Tamoxifen based on CYP2D6 genotype
- Medical Genetics Summaries (NCBI) — Tamoxifen Therapy and CYP2D6 Genotype
- MedlinePlus Genetics — CYP2D6 gene
- U.S. Food and Drug Administration — Table of Pharmacogenomic Biomarkers in Drug Labeling
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
What a poor metaboliser result meansThe label explained across every medicine, not only tamoxifenIntermediate metaboliser results and doseThe in-between result, and why advice on it variesCarrying your drug-gene result forwardHow to make sure future doctors see itWhich cancer drugs have a gene test firstThe short list where testing is standard
Talk to us
Wondering whether a CYP2D6 result changes your tamoxifen plan?
Bring the report and a list of every medicine you take. An oncologist will explain what it means for your treatment and what it does not. One helpline serves every CION centre.